Mitoxantrone as a Substitute for Daunorubicin During Induction in Newly Diagnosed Lymphoblastic Leukemia and Lymphoma

BACKGROUND: Daunorubicin, a component of the four-drug induction chemotherapy regimen for de novo pediatric high-risk acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), was unavailable in 2011 due to a national drug shortage. During this time, our institution substituted mitoxantro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pediatr Blood Cancer
Asıl Yazarlar: Nickel, Robert S., Keller, Frank, Bergsagel, John, Cooper, Todd, Daves, Marla, Sabnis, Himalee, Lew, Glen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317248/
https://ncbi.nlm.nih.gov/pubmed/24357218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24892
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller